Quick Answer
RESMED INC reported Cash and Equivalents of $1.21 billion for fiscal year 2025.
RESMED INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.21B | +407.4% |
| 2024 | $238.36M | +4.6% |
| 2023 | $227.89M | -16.7% |
| 2022 | $273.71M | -7.3% |
| 2021 | $295.28M | -36.2% |
| 2020 | $463.16M | +214.8% |
| 2019 | $147.13M | -22.0% |
| 2018 | $188.70M | -77.0% |
| 2017 | $821.93M | +12.4% |
| 2016 | $731.43M | +2.0% |
| 2015 | $717.25M | -20.8% |
| 2014 | $905.73M | +3.4% |
| 2013 | $876.05M | +8.2% |
| 2012 | $809.54M | +10.1% |
| 2011 | $735.27M | +50.4% |
| 2010 | $488.78M | +17.6% |
| 2009 | $415.65M | +29.5% |
| 2008 | $321.08M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.42B | +171.5% | +2.4% |
| September 30, 2025 | $1.38B | +224.6% | +14.4% |
| June 30, 2025 | $1.21B | +407.4% | +29.7% |
| March 31, 2025 | $932.71M | +292.0% | +78.7% |
| December 31, 2024 | $521.94M | +148.3% | +22.4% |
| September 30, 2024 | $426.36M | +103.9% | +78.9% |
| June 30, 2024 | $238.36M | +4.6% | +0.2% |
| March 31, 2024 | $237.91M | +4.4% | +13.2% |
- RESMED INC showed an increase of +407.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, RESMED INC’s cash and equivalents has grown by 276.7% (from $321.08 million to $1.21 billion).
- The most recent figure is from RESMED INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 8, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: